NASONEX ALLERGY AND CONGESTION 50 MCG — DIN 02410524
MOMETASONE FUROATE : 50 MCG · MERCK CANADA INC · SPRAY, METERED DOSE · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is NASONEX ALLERGY AND CONGESTION?
NASONEX ALLERGY AND CONGESTION 50 MCG contains MOMETASONE FUROATE : 50 MCG. It is listed in the Health Canada Drug Product Database under DIN 02410524, held by MERCK CANADA INC, supplied as SPRAY, METERED DOSE for NASAL administration. Health Canada currently lists it as cancelled pre market, status dated 17-Aug-2021. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is NASONEX ALLERGY AND CONGESTION used for?
Treatment of the symptoms of seasonal or perennial allergic rhinitis in adults and children 12 years of age and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Mometasone cost around the world?
Mometasone is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 6 | 59 | AUD███.██ |
| Greece | producer price (ex-factory) | 16 | 16 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 7 | 7 | EUR███.██ |
| United Kingdom | hospital | 5 | 5 | GBP███.██ |
| Hungary | producer price (ex-factory) | 4 | 4 | HUF███.██ |
| Morocco | PPV (public price) | 2 | 3 | MAD███.██ |
| South Africa | single exit price | 2 | 2 | ZAR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
97 pack listings across 43 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Mometasone pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Mometasone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Mometasone, across 9 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 2 | 1 | APO-MOMETASONE, NASAL ALLERGY AND CONGESTION RELIEF | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 1 | MOSASPRAY, SANDOZ MOMETASONE | Sourceable in Canada |
| ORGANON CANADA INC. | 1 | 1 | NASONEX | Sourceable in Canada |
| SANIS HEALTH INC | 1 | 1 | MOMETASONE | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 1 | 1 | MOMETASONE | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | TEVA-MOMETASONE | Sourceable in Canada |
| MERCK CANADA INC | 1 | 0 | NASONEX ALLERGY AND CONGESTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MCG |
|---|---|
| Dosage form | SPRAY, METERED DOSE |
| Route | NASAL |
| Pack configuration (monograph) | Supplied in a single pack (1 bottle) or dual pack (2 bottles). Available in 60 and 140 metered dose sizes. |
| Storage | Store between 2° and 25°C and protected from light. Do not freeze. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Mometasone |
|---|---|
| ATC code | R01AD09 |
| AHFS class | 52:08.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02410524 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2410524 |
| Brand name | NASONEX ALLERGY AND CONGESTION |
| Generic / active ingredient | MOMETASONE FUROATE : 50 MCG |
| Market authorization holder | MERCK CANADA INC |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | R01AD09 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R01AD |
| Current status | CANCELLED PRE MARKET |
| Status date | 17-Aug-2021 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults and children ≥12: 2 sprays (50 mcg/spray) in each nostril once daily (200 mcg total). Maintenance: 1 spray per nostril. Max: 4 sprays per nostril. Shake well and prime before use.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the drug or ingredients. Use with caution in patients with active/quiescent tuberculous infections, untreated fungal, bacterial, systemic viral infections, or ocular herpes simplex.
Warnings and precautions
Risk of adrenal insufficiency when transferring from systemic steroids. Avoid use with untreated nasal mucosal infection or recent nasal surgery/trauma until healing. Monitor for vision changes.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-MOMETASONE | 50 MCG | SPRAY, METERED DOSE | APOTEX INC | MARKETED | 02403587 |
| MOMETASONE | 50 MCG | SPRAY, METERED DOSE | SANIS HEALTH INC | MARKETED | 02519127 |
| MOMETASONE | 50 MCG | SPRAY, METERED DOSE | SIVEM PHARMACEUTICALS ULC | MARKETED | 02551756 |
| NASONEX | 50 MCG | SPRAY, METERED DOSE | ORGANON CANADA INC. | MARKETED | 02238465 |
| SANDOZ MOMETASONE | 50 MCG | SPRAY, METERED DOSE | SANDOZ CANADA INCORPORATED | MARKETED | 02449811 |
| TEVA-MOMETASONE | 50 MCG | SPRAY, METERED DOSE | TEVA CANADA LIMITED | MARKETED | 02475863 |
| MOSASPRAY | 50 MCG | SPRAY, METERED DOSE | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 02455870 |
| NASAL ALLERGY AND CONGESTION RELIEF | 50 MCG | SPRAY, METERED DOSE | APOTEX INC | APPROVED | 02451905 |
2 · Same class — other molecules in ATC R01AD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Mometasone | APO-MOMETASONE · MOMETASONE · MOSASPRAY · NASAL ALLERGY AND CONGESTION RELIEF · +4 more | 9 | 6 | Yes |
| Fluticasone | 24HR NASAL ALLERGY RELIEF · ALLERGY RELIEF NASAL SPRAY · APO-FLUTICASONE · FLONASE - AEM-SUS NAS 50MCG/MD · +5 more | 9 | 4 | Yes |
| Budesonide | MYLAN-BUDESONIDE AQ · RHINOCORT AQUA · RHINOCORT AQUA 100MCG · RHINOCORT TURBUHALER 100 MCG/DOSE | 5 | 3 | Yes |
| Triamcinolone | APO-TRIAMCINOLONE AQ · NASACORT · NASACORT ALLERGY 24HR · NASACORT AQ · +1 more | 5 | 3 | Yes |
| Fluticasone, Combinations | APO-AZELASTINE/FLUTICASONE · DYMISTA · MYLAN-AZELASTINE/FLUTICASONE | 3 | 3 | Yes |
| Beclomethasone | APO-BECLOMETHASONE NASAL SPRAY · BECLOMETHASONE AQUEOUS NASAL SPRAY 50MCG/METERED DOSE · BECLOMETHASONE DIPROPIONATE NAS-SPR 50MCG/AEM · BECLOMETHASONE DIPROPIONATE NASAL INHALER · +8 more | 13 | 2 | Yes |
| Ciclesonide | APO-CICLESONIDE · OMNARIS · OMNARIS HFA | 3 | 1 | Yes |
| Fluticasone Furoate | AVAMYS | 1 | 1 | Yes |
| Mometasone, Combinations | RYALTRIS | 1 | 1 | Yes |
| Flunisolide | APO-FLUNISOLIDE NASAL SPRAY · NOVO-FLUNISOLIDE · PMS-FLUNISOLIDE · RATIO-FLUNISOLIDE · +2 more | 6 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R01AA | Ephedrine · Oxymetazoline · Phenylephrine · Xylometazoline | 76 | 18 |
| R01AX | Combinations · Ipratropium Bromide · Various | 42 | 4 |
| R01AB | Ephedrine · Naphazoline · Oxymetazoline · Phenylephrine | 12 | 1 |
| R01AC | Cromoglicic Acid · Levocabastine | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is NASONEX ALLERGY AND CONGESTION called?
The same molecule, Mometasone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Novasone | Latin | Australia |
| Elocon | Latin | Australia |
| Zatamil | Latin | Australia |
| Elocon Alcohol Free | Latin | Australia |
| GLENMARK MOMETASONE | Latin | Australia |
| GLENMARK MOMETASONE Alcohol Free | Latin | Australia |
| NASONEX | Latin | Morocco |
| Aspen Mometasone Cream | Latin | South Africa |
| Rhinimet | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.